Globally, pancreatic cancer is the 12th most common cancer in men and 11th most common cancer in women. Addiction to cigarettes and health history are considered to be the foremost reasons increasing the risk.
Europe Pancreatic Cancer Therapeutics & Diagnostics Market-Market Dynamics
The report details several factors driving and restraining the market, some of which are listed below.
Some factors contributing to the growth of the market are:
Large number of unmet needs related to the disease, attracting many multi-national companies to invest in this division
Increasing healthcare expenditure
Technological developments & drug innovations with regard to the pancreatic cancer
Growing concern across the world
Some factors limiting the growth of the market are:
Difficulty in diagnosis during the early stages
Limited treatment options, especially when the disease has spread to other organs or parts of the body
Inadequate results after treatment
Low success rates in clinical trials for cancer drugs
High cost associated with the treatment
High toxicity of drugs
The European pancreatic cancer therapeutics & diagnostic market is segmented based on the type of cancer into endocrine and exocrine cancers. By the type of treatment, the market is segmented into surgery, chemotherapy, radiation therapy and targeted therapy. By the major tests, the market has been segmented into biopsy, endoscopic ultrasound, laparoscopy and CT scan ERCP. On the basis of geography, the market has been segmented into Germany, France, Spain, Italy, the UK and Rest of Europe.
Major Companies in the Sector Include:
This Report Offers:
Market definition along with identification of key drivers and restraints for the market.
Market analysis with region-specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
1.1 Market Definition
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Large Number of Unmet Needs in the Disease
3.1.2 Increase in the Healthcare Expenditure
3.1.3 Increasing Concern across the Globe
3.2 Market Restraints
3.2.1 Inadequate Results after Treatment
3.2.2 Difficulties in Early Diagnosis
3.2.3 High Cost Associated with the Treatment
3.2.4 Low Success Rate in Clinical Trials for Cancer Drugs
3.3 Market Opportunities
3.4 Market Threats
4. Porterâ€™s Five Force Analysis
4.1 Bargaining Power of Suppliers
4.2 Bargaining Power of Buyers
4.3 Degree of Competition
4.4 Threat of Substitution
4.5 Threat of New Entrants
5. Market Segmentation
5.1 Europe Pancreatic Cancer Therapeutics & Diagnostic Market, by Cancer Type
5.1.1 Exocrine Cancers
22.214.171.124 Pancreatic Adenocarcinoma
126.96.36.199 Acinar Cell Carcinoma
5.1.2 Endocrine Cancers (PanNETs)
5.2 Europe Pancreatic Cancer Therapeutics Market
5.2.3 Radiation Therapy
5.2.4 Chemoradiation Therapy
5.2.5 Targeted Therapy
5.3 Europe Pancreatic Cancer Diagnostics Market
5.3.2 Confirmatory Needle biopsy
5.3.3 Endoscopic Ultrasound
5.3.5 CT Scan
5.3.6 PET Scan
5.4 Europe Pancreatic Cancer Therapeutics Market, By Region
5.4.6 Rest of Europe
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to New Market Players
7. Company Profiles
7.1 Amgen, Inc.
7.2 Eli Lilly and Company
7.3 Celgene Corporation
7.4 Clovis Oncology, Inc.
7.5 Novartis AG
7.6 Threshold Pharmaceuticals, Inc.
7.7 Incyte Corp
7.8 Merrimack Pharmaceuticals Inc.
7.9 Roche Ltd
7.10 NewLink Genetics